Navigation Links
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
Date:5/2/2008

d is currently being evaluated in a Phase 2a trial in CIAS, with top-line results expected in the fourth quarter of 2008. The trial is expected to enroll approximately 160 patients and is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with CIAS. In addition, Memory Pharmaceuticals and Roche recently expanded their schizophrenia development program for MEM 3454 to include a biomarker study, which will be funded by Roche. Memory Pharmaceuticals expects to initiate the biomarker trial this summer, with results expected by early 2009.

MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.

Conference Call Information

Memory Pharmaceuticals will hold a conference call today, May 2, 2008 at 9:00 a.m. EDT to discuss this announcement. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Friday, May 2, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.314.4483

Telephone (international): 617.213.8049

Participant Passcode: 38691567

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Friday, May 2, 2008, until Friday, May 9, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 95627100. An au
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
2. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
3. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
4. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
5. Roche responds to announcement of IDEAL hepatitis C trial results
6. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
7. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
8. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
9. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
10. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ® Technologies, Inc., the leader in non-invasive, accelerated orthodontic ... to continued demand from orthodontists and patients for safe, ... locations in the U.S. and Canada ... the only FDA-cleared Class II medical device that has ... much as 50 percent.  A recent ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 /PRNewswire/ ... that Jennifer Simpson , Ph.D., M.S.N., C.R.N.P. ... by the Company,s Board of Directors, effective immediately.  ... Chief Executive Officer of Delcath since September 2014 ... from September 2013 to September 2014.  She joined ...
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
Breaking Medicine Technology:OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3Delcath Names Dr. Jennifer Simpson President And CEO 2Delcath Names Dr. Jennifer Simpson President And CEO 3Delcath Names Dr. Jennifer Simpson President And CEO 4LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
... study broadens Phase 3 clinical program to further evaluate the ... April 15 Pfizer (NYSE: PFE ) and ... announced the initiation of a 12-month, Phase 3 clinical trial ... CONCERT, is designed to evaluate the safety and efficacy of ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... study to evaluate the safety and tolerability of PCI-32765,an ... Btk,as a potential treatment for patients with relapsed or ... first Btk selective inhibitor to,be tested in humans, and ...
Cached Medicine Technology:Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 2Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 3Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5
(Date:5/26/2015)... Securityhunter has been awarded ... United States Department of Health and Human Services (HHS) ... MATOC was awarded through the General Services Administration (GSA) ... PSC, which is a fee-for-service agency. The award is ... and is an enterprise–wide physical security and security system ...
(Date:5/26/2015)... May 26, 2015 In God’s Unstoppable ... her as she writes an unforgettable story of how ... her life. The first black student to desegregate Evangeline ... beaten by some students, treated harshly by a few ... motivating personal phone conversation with Dr. Martin Luther King, ...
(Date:5/26/2015)... Over 700 doctors, nutritionists, nurses, and public ... secretaries of the U.S. Department of Agriculture and the ... to embrace the 2015 Dietary Guidelines Advisory Committee’s recommendations ... health, economic prosperity, and our nation’s food security. , ... including: Dr. David Katz, founding director of the Yale ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The American College ... join them for the Open House/Free Application Day on Wednesday, ... go until 4 p.m. and will be held at ACTCM ... CA. , After checking in, attendees will be greeted with ... a tour of the campus at 11:45 a.m. Lunch will ...
(Date:5/26/2015)... Irwin Gross, M.D., Accumen, Inc.’s ... Blood Management (PBM) initiative at Eastern Maine Medical Center ... more than 60 percent and improved patient outcomes over ... an article in the May 2015 edition of Transfusion, ... cell loss, less acute kidney injury and cut the ...
Breaking Medicine News(10 mins):Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Grace Sibley Releases Second Book, God's Unstoppable Favor 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 3Health News:ACTCM to Host Summer Open House 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3
... leadership and entrepreneurial expertise to ... ... the,creator of Dreamerz, the first ever all-natural sleep beverage, today,announced Gilbert ... newest member of the San Francisco-based company,s,Board of Directors. Pritchard brings ...
... issues while being treated by specialists for cancer improves ... the December 20 issue of the Journal of Clinical ... Indiana University School of Medicine, the Regenstrief Institute and ... to look at the effect of primary care on ...
... PALO ALTO, Calif., Dec. 27 Garry W. Rogerson,President ... at the 26th,annual JPMorgan Healthcare Conference in San Francisco ... A live webcast of the presentation will be ... . Go to, http://www.varianinc.com and click on "Investors." ...
... Computer Sciences,Corporation (NYSE: CSC ) ... extension to,a global information technology (IT) applications ... Under the five-year agreement, CSC will continue ... for Sun,s business,applications portfolios -- including finance, ...
... is also prone to pulmonary fibrosis, which has no cure ... of terrier could stop scientists from barking up the wrong ... , The illness, called idiopathic pulmonary fibrosis (IPF), affects 128,000 ... kills more than 40,000 people in the United States annually ...
... and Protect Themselves in New Year, VAN NUYS, ... they have cervical cancer/HPV this year,and nearly 4,000 will ... during Cervical Health Awareness Month, the National Cervical,Cancer Coalition ... the Pap test as a screening tool for cervical ...
Cached Medicine News:Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 2Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 3Health News:Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:Terriers Join Fight Against a Killer Disease in Humans 2Health News:Terriers Join Fight Against a Killer Disease in Humans 3Health News:Terriers Join Fight Against a Killer Disease in Humans 4Health News:National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: